Danaher (NYSE:DHR – Get Free Report) posted its quarterly earnings data on Tuesday. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14, Briefing.com reports. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company posted $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year.
Danaher Stock Performance
Shares of DHR opened at $250.00 on Friday. Danaher has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a 50 day moving average price of $270.43 and a two-hundred day moving average price of $260.43. The firm has a market capitalization of $185.17 billion, a P/E ratio of 42.01, a P/E/G ratio of 4.49 and a beta of 0.83.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s payout ratio is 18.31%.
Insider Activity at Danaher
Analyst Ratings Changes
DHR has been the topic of a number of research analyst reports. Leerink Partners upped their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. KeyCorp raised their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday. Royal Bank of Canada cut their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.
View Our Latest Research Report on DHR
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Quiet Period Expirations Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- About the Markup Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- What Does a Stock Split Mean?
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.